Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102921 · ClinicalTrials.gov registry record · Phase 2
Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00102921 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 70 participants.
The verdict
NCT00102921, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this research study is to investigate the effects of an investigational medication, called CCX282-B, on safety and on the some of the symptoms of Crohn's Disease in patients who are experiencing an active flare-up of moderate to severe Crohn's Disease.
Interventions
- DRUG CCX282-B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102921
The ClinicalTrials.gov registry entry for NCT00102921 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CCX282-B is the first listed.
NCT00102921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00102921 about?
NCT00102921 is a clinical study titled "Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease". The purpose of this research study is to investigate the effects of an investigational medication, called CCX282-B, on safety and on the some of the symptoms of Crohn's Disease in patients who are experiencing an active flare-up of moderate to severe Crohn's Disease.
What is the current status of trial NCT00102921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2004-08. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00102921?
The interventions under investigation include: CCX282-B (DRUG).
Who is sponsoring clinical trial NCT00102921?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.